PBIGF (Paradigm Biopharmaceuticals) Interest Expense : $-0.01 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Paradigm Biopharmaceuticals's interest expense for the six months ended in Dec. 2024 was $ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Paradigm Biopharmaceuticals's Operating Income for the six months ended in Dec. 2024 was $ -4.07 Mil. Paradigm Biopharmaceuticals's Interest Expense for the six months ended in Dec. 2024 was $ -0.00 Mil. Paradigm Biopharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Paradigm Biopharmaceuticals Interest Expense Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Interest Expense Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Interest Expense

Get a 7-Day Free Trial

-0.02

-0.03

-0.02

-0.01

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Interest Expense	Get a 7-Day Free Trial														-0.01	-0.01	-	-0.01	-

Paradigm Biopharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.01 Mil.

Paradigm Biopharmaceuticals (OTCPK:PBIGF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Paradigm Biopharmaceuticals's Interest Expense for the six months ended in Dec. 2024 was $-0.00 Mil. Its Operating Income for the six months ended in Dec. 2024 was $-4.07 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2024 was $0.06 Mil.

Paradigm Biopharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Paradigm Biopharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Paradigm Biopharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

P86:Germany PAR:Australia

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.